PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age \<80 years
• Cytological or histological diagnosis of colorectal adenocarcinoma
• Two or three asymptomatic lung nodules smaller than 25 mm
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
• Available Formalin Fixed Paraffin Embedded (FFPE) of resected primary tumor
• Negative pregnancy test for all potentially childbearing women
• Patient candidates to SBRT
Locations
Other Locations
Italy
Istituto Nazionale Tumori - Fondazione G. Pascale
RECRUITING
Napoli
Contact Information
Primary
Paolo Muto, MD
p.muto@istitutotumori.na.it
0815903398
Backup
Alessandro Ottaiano, MD
a.ottaiano@istitutotumori.na.it
0815903510
Time Frame
Start Date: 2021-10-06
Estimated Completion Date: 2025-03
Participants
Target number of participants: 25
Treatments
Other: Liquid biopsy
Blood samples for liquid biopsy
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute, Naples